arrow
R

Richard D. Gelber

dana-farber cancer institute and harvard medical school and harvard t.h. chan school of public health and frontier science & technology research foundation
H指数:133
被引数:9.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

“Neoadjuvant Trastuzumab Deruxtecan for High-Risk HER2-Positive Early Breast Cancer: Does the Evidence Support Its Use as a New Standard-of-Care?”

新辅助治疗中曲妥珠单抗德鲁替康用于高危HER2阳性早期乳腺癌:现有证据是否支持其作为新的标准治疗方案?

2026-05-140
PRE
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT

TEXT和SOFT研究中激素受体阳性早期乳腺癌女性患者报告抑郁的预后价值

Cancer
IF5.1
2025-09-230
PRE
Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial

POSITIVE试验中,预测乳腺癌患者为尝试生育而中断辅助内分泌治疗时生育力的激素因素

2025-07-260
OAAI
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

风险降低手术与年轻BRCA携带者乳腺癌患者生存期的关联:一项国际队列研究

2025-05-080
PRE
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial

在APHINITY试验中,他汀类药物使用与早期HER2阳性乳腺癌患者生存结局的关联

2025-04-280
OA
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis

停用免疫检查点抑制剂的晚期实体瘤患者的结局: 系统回顾和荟萃分析

2024-07-010
OAAI
Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy
2024-05-020
PRE
Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
2024-05-023
PRE
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium (vol 203, pg 351, 2023)

原发转移性乳腺癌患者的原发肿瘤手术: 比利时一项基于全国人口的回顾性队列研究 (203卷,351页,2023页)

2024-04-090
OA
Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

初发转移性乳腺癌患者原发肿瘤的手术治疗:比利时一项全国性的基于人群的回顾性队列研究

2023-10-259
PRE
Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

乳腺癌后中断内分泌治疗以尝试怀孕

2023-05-0489
OA
Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)
2023-03-014
PRE
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
2023-03-013
PRE
Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

OlympiA iii期试验中辅助olaparib治疗BRCA1/2中germime致病变异和高危早期乳腺癌患者的总生存率

2022-12-01198
OAAI
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
2022-05-0111
OA
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial
2022-02-1612
OAAI